India's Lupin Limited has entered into partnership with China's Shenzhen Foncoo Pharmaceutical Co. Ltd to take generic medicines to patients in China, the Indian company said in its filing with the Bombay Stock Exchange, Wednesday.

"Lupin is committed to serving the healthcare needs of the Chinese population by providing high quality generic and complex generic products," said Fabrice Egros, President of Growth Markets at Lupin.

"We expect that the successful launch of our first product in China will come smoothly and soon. We will also continue exploring more opportunities to work with Lupin for providing more and more high-valued and complex medicines to the Chinese physicians and patients," said Peng Yan, general manager of Foncoo.